MedTrace Logo

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2020-01-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

Conditions

  • Parkinson Disease

Interventions

DRUG

Isradipine

Oral capsules Isradipine IR, up to 10 mg, taken twice daily

DRUG

Placebo (for Isradipine)

Sugar Pill manufactured to look like Isradipine but has no active ingredients

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • The Parkinson Study Group

    collaborator NETWORK

  • University of Rochester

    lead OTHER

Principal Investigators

  • Tanya Simuni, MD · Northwestern University

  • Robert Holloway, MD MPH · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02168842 on ClinicalTrials.gov